Literature DB >> 28129095

T Lymphocytes in Histiocytic Sarcomas of Flat-Coated Retriever Dogs.

A Marcinowska1, F Constantino-Casas1, T Williams1, T Hoather1, B Blacklaws1, J Dobson1.   

Abstract

Flat-Coated Retriever dogs are predisposed to the development of histiocytic sarcoma (HS), a poorly differentiated, highly malignant neoplasm. The authors have previously documented a significant lymphocytic infiltrate in such tumors. The objective of this study was to examine the presence and expression of regulatory T cells in HS tumor samples. Forty tumors were included in this study. All tumors were immunolabeled for CD3, CD79a, CD25, CD45RA, and FOXP3. The proportion of positive cells was compared between tumors presenting as a localized primary soft tissue mass (soft tissue origin HS) and disseminated HS affecting viscera, especially the spleen (splenic origin HS). By immunohistochemistry, 95% of infiltrating T cells were positive for Foxp3 in all sections, suggesting the presence of regulatory T cells. The proportion of cells positive for FOXP3 was higher in the tumors arising in soft tissues, whereas the proportion of CD45RA-positive cells was higher in the splenic origin HS. Canine HS has an aggressive clinical behavior and is uniformly fatal. The difference in the proportion of tumor-infiltrating lymphocytes positive for these 2 markers in the 2 locations may represent differences in tumor microenvironment between the 2 sites.

Entities:  

Keywords:  Flat-Coated Retriever; cancer immunology; hematologic neoplasms; histiocytic sarcoma; regulatory T cells; tumor microenvironment; tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 28129095     DOI: 10.1177/0300985817690208

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  1 in total

1.  Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.

Authors:  Jennifer A Lenz; Charles-Antoine Assenmacher; Victoria Costa; Katie Louka; Suzanne Rau; Nicholas S Keuler; Paul J Zhang; Robert G Maki; Amy C Durham; Enrico Radaelli; Matthew J Atherton
Journal:  Cancer Immunol Immunother       Date:  2021-08-20       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.